Century Therapeutics, Inc. announced it has entered into a securities purchase agreement with a select group of institutional investors and accredited investors to issue 15,873,011 shares at a issue price of $3.78 per share for gross proceeds of $59,999,981.58 on April 11, 2024. The transaction will include participation from new investors including Bain Capital Life Sciences, Adage Capital Partners LP, Octagon Capital, and Superstring Capital, and existing investors including Casdin Capital, Boxer Capital, Venrock Healthcare Capital Partners, and DAFNA Capital Management, LLC, as lead investors. The transaction is expected to close on April 15, 2024, subject to customary closing conditions.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.04 USD | +4.47% | +2.70% | -8.43% |
Apr. 12 | Piper Sandler Adjusts Price Target on Century Therapeutics to $9 From $10, Maintains Overweight Rating | MT |
Apr. 11 | Syncona agrees to sell stake in investee company for GBP7.4 million | AN |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-8.43% | 240M | |
+0.67% | 42.19B | |
+44.30% | 40.15B | |
-6.20% | 28.31B | |
+6.55% | 24.63B | |
-21.66% | 18.2B | |
+29.96% | 12.01B | |
-1.57% | 11.76B | |
+16.03% | 10.4B | |
-4.80% | 9.94B |
- Stock Market
- Equities
- IPSC Stock
- News Century Therapeutics, Inc.
- Century Therapeutics, Inc. announced that it expects to receive $59.999982 million in funding from a group of investors